Lonza Stretches Transfection Dimensions – Launch of 4D-Nucleofector® System
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Lonza’s new 4D-Nucleofector® System is lifting the Amaxa® Nucleofector® Technology to the next dimension. In response to comprehensive user feedback Lonza engineers and scientists have developed a system which is designed for maximum flexibility.
This Nucleofection® Platform allows transfection of cells in various formats and throughputs using the same Nucleofection® Conditions. 100 µl single Nucleocuvettes® are suited for high cell numbers at low throughput while 20 µl 16-well Nucleocuvette® Strips enable transfection of low cell numbers at medium throughput.
Furthermore, primary neurons can now be transfected at later developmental stages by Nucleofection® in adherence. Being a modular tool, the 4D-Nucleofector® System is designed to be prepared for upcoming transfection challenges.
Nucleofection® is known as the first efficient non-viral transfection method for primary cells and difficult-to-transfect cell lines.
This Nucleofection® Platform allows transfection of cells in various formats and throughputs using the same Nucleofection® Conditions. 100 µl single Nucleocuvettes® are suited for high cell numbers at low throughput while 20 µl 16-well Nucleocuvette® Strips enable transfection of low cell numbers at medium throughput.
Furthermore, primary neurons can now be transfected at later developmental stages by Nucleofection® in adherence. Being a modular tool, the 4D-Nucleofector® System is designed to be prepared for upcoming transfection challenges.
Nucleofection® is known as the first efficient non-viral transfection method for primary cells and difficult-to-transfect cell lines.
